Postdialysis urea rebound: determinants and influence on dialysis delivery in chronic hemodialysis patients. 1996

M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Québec, Canada.

We measured postdialysis urea rebound (PDUR) 30 minutes after dialysis in 92 chronic hemodialysis patients. The impact of PDUR on the estimation of dialysis delivery assessed by urea reduction ratio and Kt/V was evaluated. Total recirculation, access plus cardiopulmonary, was measured at the end of dialysis with the two-needle low blood flow method. The mean age of the 92 patients (49 men and 43 women) was 59.6 +/- 1.4 years. Thirty-eight patients had been receiving erythropoietin therapy for more than 3 months. Fifteen patients had central venovenous access and 77 had peripheral arteriovenous access. Sixty-five patients were dialyzed using hemophan membranes and 27 were dialyzed using polyacrylonitrile membranes. The mean blood flow rate was 240 +/- 28 mL/min and the mean length of the hemodialysis sessions was 3.6 +/- 0.1 hours. Kt/V was calculated with Daugirdas' second-generation formula. The mean PDUR was 16.6% +/- 0.8% (range, 2% to 44%) (n = 92), and significantly decreased the mean urea reduction ratio from 61.7% +/- 0.8% to 55.5% +/- 0.9%, the mean Kt/V from 1.14 +/- 0.03 to 0.97 +/- 0.02, and the mean protein catabolic rate from 1.06 +/- 0.04 to 0.98 +/- 0.02 (P = 0.0001). The effective Kt/V at 30 minutes postdialysis was well predicted by using a recently proposed equation: eKt/V30 = Kt/Vsp - (0.6 x Kt/Vsp/t) + 0.03, with a mean value corresponding also to 0.97 +/- 0.02. However, this estimation was less predictive in patients with very high PDUR. Moreover, PDUR showed only a weak negative correlation with dialysis session length (r = -0.28) and predialysis patient weight (r = -0.29), and showed no correlation with predialysis serum urea level or with blood flow rate. However, dialysis efficiency, as assessed by K/V, presented a correlation of 0.54 with both PDUR and the difference in Kt/V when using urea immediately postdialysis and at 30 minutes. The mean total recirculation was 7.4% +/- 0.6% (n = 86). Postdialysis urea rebound, calculated between 30 or 120 seconds and 30 minutes after dialysis to deduce the influence of recirculations, was reduced but remained important with a mean of 11.8% +/- 0.7%. Thus, total recirculation contributed to nearly 30% of PDUR. The 24 patients with PDUR > or = 20% were compared with the 68 patients with PDUR lower than 20%: women and patients with higher K/V and higher total recirculation presented greater PDUR. Because of relatively few predictive factors for PDUR, its potential considerable impact on dialysis delivery estimation, and the influence of recirculations on the total PDUR amount, total recirculation and PDUR should be determined on an individual basis in chronic hemodialysis patients. The equation proposed to estimate effective Kt/V at 30 minutes is accurate in most patients with PDUR lower than 30% and is a simple alternative.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008567 Membranes, Artificial Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION. Artificial Membranes,Artificial Membrane,Membrane, Artificial
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002482 Cellulose A polysaccharide with glucose units linked as in CELLOBIOSE. It is the chief constituent of plant fibers, cotton being the purest natural form of the substance. As a raw material, it forms the basis for many derivatives used in chromatography, ion exchange materials, explosives manufacturing, and pharmaceutical preparations. Alphacel,Avicel,Heweten,Polyanhydroglucuronic Acid,Rayophane,Sulfite Cellulose,alpha-Cellulose,Acid, Polyanhydroglucuronic,alpha Cellulose
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000180 Acrylic Resins Polymers of high molecular weight which are derived from acrylic acid, methacrylic acid or other related compounds and are capable of being molded and then hardened to form useful components. Acrylic Resin,Resin, Acrylic,Resins, Acrylic

Related Publications

M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
February 2000, Nephron,
M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
October 2017, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
January 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation,
M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
January 1992, Pharmacotherapy,
M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
January 1998, Blood purification,
M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
January 1974, The Journal of the Egyptian Medical Association,
M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
September 1999, Kidney international,
M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
January 2004, Journal of the American Society of Nephrology : JASN,
M Leblanc, and R Charbonneau, and G Lalumière, and P Cartier, and C Déziel
April 2005, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
Copied contents to your clipboard!